LupusTrials.org CATEGORIES: Lupus Nephritis The purpose of this study is to determine if AMG 570 could be a useful therapeutic agent in the current treatment landscape where subjects with systemic lupus erythematosus (SLE) have ongoing disease activity despite treatment with standard of care therapies. To Learn More Contact Reference Study ID Number: CA41705 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. …
Archives: Trials
JBT-101 in Systemic Lupus Erythematosus (SLE)
The objective of this study is to evaluate the efficacy, safety, and tolerability of JBT-101 (also known as lenabasum) in systemic lupus erythematosus (SLE). To Learn More Contact Visit ClinicalTrials.gov to search for sites near you and reach out to Contact listed. ClinicalTrials.gov identifier: NCT03093402 …
Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)
First filed August, 2019, updated January, 2021 CATEGORIES: General SLE This phase 2b, multi-center, double-blind, randomized, placebo-controlled, 52-week, dose-ranging study is investigating AMG 570 in subjects with active SLE who have had inadequate response to SOC therapies including oral corticosteroids (OCS), immunosuppressants and immunomodulators. This study is being offered at 24 LuCIN sites – institutions …
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
First filed March 2020, Updated January 2021; Recruiting CATEGORIES: General SLE The purpose of this Phase 3 study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease activity. This study is being offered …
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE)
The PROMISSE Study is a prospective observational study that will follow 700 pregnant patients who will be grouped and analyzed according to the presence or absence of aPL antibodies and preexisting SLE. The data obtained will be analyzed and used to explore mechanisms and predictors of poor fetal outcome. To Learn More Contact Marta M. …
Belimumab (BENLYSTA®) Pregnancy Registry (BPR) – Prospective Cohort Study of Pregnancy Outcomes Following Benlysta Exposure Within 4 Months Prior to and/or During Pregnancy
This global Belimumab Pregnancy Registry will collect prospective data on pregnancies in women with systemic lupus erythematosus (SLE) who have First filed belimumab within the 4 months prior to and/or during pregnancy. The registry will also evaluate outcomes of infants born to mothers who were exposed to belimumab within the 4 months prior to and/or …
A Phase 2 Safety and Efficacy Study of Filgotinib and GS-9876 in Participants with Lupus Membranous Nephropathy (LMN)
CATEGORIES: Lupus Nephritis The purpose of thisPhase 3 study is assess the long-term safety and tolerability of voclosporin compared with placebo for up to an additional 24 months following completion of treatment in the AURORA 1 study in subjects with lupus nephritis (LN). To Learn More Contact GS-US-437-4093@gilead.com ClinicalTrials.gov identifier: NCT03285711 …
Study to Evaluate BIIB059 in CLE With or Without SLE (LILAC)
This multicenter, Phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study intends to evaluate the efficacy of BIIB059 in reducing skin disease activity in participants with systemic lupus erythematosus (SLE) (Part A), and in participants with active cutaneous lupus erythematosus (CLE) with or without systemic manifestations (Part B), and to investigate the dose response relationship in …
Role of PPAR-y Anonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
This Phase 1/2 randomized study sponsored by the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is looking at how well pioglitazone improves blood vessel function and decreases blood vessel inflammation for patients with lupus. The study is being conducted at the NIH Clinical Center in Bethesda, Maryland. To Learn More Contact …
Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) (LILAC)
The primary objective of the study is to evaluate the efficacy of BIIB059 in reducing skin disease activity in participants with systemic lupus erythematosus (SLE) (Part A), and in participants with active cutaneous lupus erythematosus (CLE) with or without systemic manifestations (Part B), and to investigate the dose response relationship in participants with active SLE …